Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

BACKGROUND: The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. METHODS: Given the high degree of genetic heterogeneity in melanoma, we sought to understand the breadth of variation in PI3K signalling in the large NZM panel of early passage cell lines developed from...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Tran, Khanh B., Kolekar, Sharada, Jabed, Anower, Jaynes, Patrick, Shih, Jen-Hsing, Wang, Qian, Flanagan, Jack U., Rewcastle, Gordon W., Baguley, Bruce C., Shepherd, Peter R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7866738/
https://ncbi.nlm.nih.gov/pubmed/33549048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-07826-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak